Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.80%
#2 Movement Movement +11.34%
#3 Victoria VR Victoria VR +7.37%
#4 DMT-NAT DMT-NAT +5.95%
#5 Cryptopia Cryptopia +5.23%
#6 COTI COTI +4.96%
#7 Lisk Lisk +4.73%
#8 Pons Pons +4.67%
#9 MarsCoin MarsCoin +4.33%
#10 Jito Jito +3.85%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Xeno Transplants Corporation Xeno Transplants Corporation

Xeno Transplants Corporation

XENO
Rank in Stocks #42146
Xeno Transplants Corporation functions as a biotechnology firm dedicated to... Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, and implement products and methodologies for public application in the field of xenotransplantation. The primary objective of this xenotransplantation research is to alleviate the critical scarcity of human cells, tissues, and organs required for medical transplants. This is achieved by pioneering techniques that enable the transfer of biological components—such as cells, tissues, and organs—from non-human species, including pigs, into human recipients. Established in 2004, Xeno Transplants Corporation maintains its headquarters in Brookline, Massachusetts.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$4.04K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade Xeno Transplants Corporation (XENO)

Category

Healthcare
Revenue for Xeno Transplants Corporation (XENO)
Revenue in Aug 2026 TTM: 0
According to Xeno Transplants Corporation latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Xeno Transplants Corporation from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR